The use of pregabalin in a patient with neuropathic pain in the course of chemotherapy-induced peripheral neuropathy – a case report Case report
Article Sidebar
Published:
Mar 31, 2022
Keywords:
neuropathic pain, chemotherapy-induced peripheral neuropathy, pregabalin
Main Article Content
Abstract
Chemotherapy-induced neuropathy (CIPN) is a frequent iatrogenic complication and a consequence of causal treatment of neoplastic disease. The risk of developing CIPN depends on the type of chemotherapy, the total dose, but also on the patients’ factors. There is currently no proven method that can prevent the occurrence of CIPN. Neuropathic pain may occur in 40% of patients with CIPN, decreases patients’ quality of life and can be treated symptomatically only, both with pharmacotherapy and non-pharmacological methods. Antiepileptics, antidepressants, opioid analgesics and topical drugs are recommended. These drugs have proven their effectiveness in the population of patients with neuropathic pain unrelated to cancer treatment, but there are still no high-quality studies assessing their effectiveness in patients with CIPN. Studies in small groups of patients available in the literature confirm the effectiveness of antiepileptic and antidepressant drugs in this group of patients, what is observed in clinical practice as well. The article presents a case of a patient with severe neuropathic pain in the course of CIPN who was successfully treated with pregabalin in combination with duloxetine.
Article Details
How to Cite
Kocot-Kępska , M. (2022). The use of pregabalin in a patient with neuropathic pain in the course of chemotherapy-induced peripheral neuropathy – a case report. Medycyna Faktow (J EBM), 15(1(54), 94-100. https://doi.org/10.24292/01.MF.0122.13
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Burgess J, Ferdousi M, Gosal D et al. Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. Oncol Ther. 2021; 9(2): 385-450. http://doi.org/10.1007/s40487-021-00168-y.
2. Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies – A growing problem for patients and health care providers. Brain Behav. 2016; 7: e00558.
3. Flatters SJL, Dougherty PM, Colvin LA. Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review. Br J Anaesth. 2017; 119: 737-49.
4. Seretny M, Currie GL, Sena ES et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014; 155: 2461-70.
5. Bennett MI, Rayment C, Hjermstad M et al. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain. 2012; 153(2): 359-65. http://doi.org/10.1016/j.pain.2011.10.028.
6. Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013; 111: 105-11.
7. Jones D, Zhao F, Brell J et al. Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer. J Cancer Surviv. 2015; 9: 1-10.
8. Boyette-Davis JA, Hou S, Abdi S et al. An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy. Pain Manag. 2018; 8: 363-75.
9. Ventzel L, Madsen CS, Karlsson P et al. Chronic pain and neuropathy following adjuvant chemotherapy. Pain Med. 2018; 19: 1813-24.
10. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention [Review]. Neuro Oncol. 2012; 14(suppl 4): iv45-54.
11. Mols F, van de Poll-Franse LV, Vreugdenhil G et al. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population. Eur J Cancer. 2016; 69: 28-38.
12. Vincenzi B, Frezza AM, Schiavon G et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer. 2013; 21(5): 1313-9.
13. Hershman DL, Lacchetti C, Dworkin RH et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014; 32(18): 1941-67.
14. Zajączkowska R, Kocot-Kępska M, Leppert W et al. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci. 2019; 20(6): 1451. http://doi.org/10.3390/ijms20061451.
15. Przeklasa-Muszyńska A, Dobrogowski J, Kocot-Kępska M. Kliniczna ocena chorego z bólem. In: Dobrogowski J, Wordliczek J, Kocot-Kępska M (ed). Ból. Wiedza w kieszeni. Termedia Wydawnictwa Medyczne, Poznań 2020: 25-34.
16. ChPL Fludarabin-Ebewe, 25 mg/ml, koncentrat do sporządzania roztworu do wstrzykiwań lub infuzji.
17. Fallon M, Giusti R, Aielli F et al.; ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018; 29(suppl 4): iv166-iv191. http://doi.org/10.1093/annonc/mdy152.
18. Finnerup NB, Attal N, Haroutounian S et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14(2): 162-73. http://doi.org/10.1016/S1474-4422(14)70251-0.
19. Chincholkar M. Analgesic mechanisms of gabapentin and effects in experimental pain models: a narrative review. Br J Anaesth. 2018; 120: 1315-34.
20. Verma V, Singh N, Singh Jaggi A. Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr Neuropharmacol. 2014; 12: 44-56.
21. Jordan RI, Mulvey MR, Bennett MI. A critical appraisal of gabapentinoids for pain in cancer patients. Curr Opin Support Palliat Care. 2018; 12(2): 108-17.
22. Aoki M, Kurauchi Y, Mori A et al. Comparison of the effects of single doses of elcatonin and pregabalin on oxaliplatin induced cold and mechanical allodynia in rats. Biol Pharm Bull. 2014; 37: 322-6.
23. Peng P, Xi Q, Xia S et al. Pregabalin attenuates docetaxel-induced neuropathy in rats. J Huazhong Univ Sci Technolog Med Sci. 2012; 32: 586-90.
24. Ling B, Coudoré F, Decalonne L et al. Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection. Neuropharmacology. 2008; 55(5): 724-8. http://doi.org/10.1016/j.neuropharm.2008.06.007.
25. Saif MW, Syrigos K, Kaley K et al. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res. 2010; 30(7): 2927-33.
26. Nihei S, Sato J, Kashiwaba M et al. Efficacy and safety of pregabalin for oxaliplatin- and paclitaxel-induced peripheral neuropathy. Gan To Kagaku Ryoho. 2013; 40: 1189-93.
27. Salehifar E, Janbabaei G, Hendouei N et al. Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial. Clin Drug Investig. 2020; 40(3): 249-57. http://doi.org/10.1007/s40261-019-00882-6.
28. Avan R, Janbabaei G, Hendouei N et al. The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane- induced sensory neuropathy: a randomized clinical trial. J Res Med Sci. 2018; 23: 52.
29. Sugimoto M, Takagi T, Suzuki R et al. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer. 2021; 21(1): 1319. http://doi.org/10.1186/s12885-021-09069-9.
30. Hincker A, Frey K, Rao L et al. Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled, crossover study. Pain. 2019; 160(8): 1835-46.
31. Derry S, Bell RF, Straube S et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019; 1: CD007076.
32. Charakterystyka produktu leczniczego: pregabalina.
33. Szczudlik A, Dobrogowski J, Wordliczek J et al. Diagnosis and management of neuropathic pain: Review of literature and recommendations of the Polish Association for the Study of Pain and the Polish Neurological Society – Part one. Neurol Neurochir Pol. 2014; 48: 262-71.
34. Lussier D. Pain Pharmacotherapy in Older Patients. W: Pain 2016: Refresher Courses, 16th World Congress on Pain.
35. Markman JD, Jensen TS, Semel D et al. Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials. Pain Pract. 2017; 17(6): 718-28. http://doi.org/10.1111/papr.12516.
36. Dworkin RH, O`Connor AB, Audette J et al. Recommendations for the pharmacological management of neuropathic pain; an overview and literature update. Mayo Clin Proc. 2010; 85(3 suppl): S3-S14.
37. Johnson P, Becker L, Halpern R et al. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. Clin Drug Investig. 2013; 33(1): 35-44.
38. Holbech JV, Jung A, Jonsson T et al. Combination treatment of neuropathic pain: Danish expert recommendations based on a Delphi process. J Pain Res. 2017; 10: 1467-75.
39. Arnold LM, McCarberg BH, Clair AG et al. Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. Postgrad Med. 2017; 129(8): 921-33. http://doi.org/10.1080/00325481.2017.1384691.
40. Song SY, Ko YB, Kim H et al. Effect of serotonin-norepinephrine reuptake inhibitors for patients with chemotherapy-induced painful peripheral neuropathy: A meta-analysis. Medicine (Baltimore). 2020; 99(1): e18653. http://doi.org/10.1097/MD.0000000000018653.
2. Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies – A growing problem for patients and health care providers. Brain Behav. 2016; 7: e00558.
3. Flatters SJL, Dougherty PM, Colvin LA. Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review. Br J Anaesth. 2017; 119: 737-49.
4. Seretny M, Currie GL, Sena ES et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014; 155: 2461-70.
5. Bennett MI, Rayment C, Hjermstad M et al. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain. 2012; 153(2): 359-65. http://doi.org/10.1016/j.pain.2011.10.028.
6. Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013; 111: 105-11.
7. Jones D, Zhao F, Brell J et al. Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer. J Cancer Surviv. 2015; 9: 1-10.
8. Boyette-Davis JA, Hou S, Abdi S et al. An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy. Pain Manag. 2018; 8: 363-75.
9. Ventzel L, Madsen CS, Karlsson P et al. Chronic pain and neuropathy following adjuvant chemotherapy. Pain Med. 2018; 19: 1813-24.
10. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention [Review]. Neuro Oncol. 2012; 14(suppl 4): iv45-54.
11. Mols F, van de Poll-Franse LV, Vreugdenhil G et al. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population. Eur J Cancer. 2016; 69: 28-38.
12. Vincenzi B, Frezza AM, Schiavon G et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer. 2013; 21(5): 1313-9.
13. Hershman DL, Lacchetti C, Dworkin RH et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014; 32(18): 1941-67.
14. Zajączkowska R, Kocot-Kępska M, Leppert W et al. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci. 2019; 20(6): 1451. http://doi.org/10.3390/ijms20061451.
15. Przeklasa-Muszyńska A, Dobrogowski J, Kocot-Kępska M. Kliniczna ocena chorego z bólem. In: Dobrogowski J, Wordliczek J, Kocot-Kępska M (ed). Ból. Wiedza w kieszeni. Termedia Wydawnictwa Medyczne, Poznań 2020: 25-34.
16. ChPL Fludarabin-Ebewe, 25 mg/ml, koncentrat do sporządzania roztworu do wstrzykiwań lub infuzji.
17. Fallon M, Giusti R, Aielli F et al.; ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018; 29(suppl 4): iv166-iv191. http://doi.org/10.1093/annonc/mdy152.
18. Finnerup NB, Attal N, Haroutounian S et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14(2): 162-73. http://doi.org/10.1016/S1474-4422(14)70251-0.
19. Chincholkar M. Analgesic mechanisms of gabapentin and effects in experimental pain models: a narrative review. Br J Anaesth. 2018; 120: 1315-34.
20. Verma V, Singh N, Singh Jaggi A. Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr Neuropharmacol. 2014; 12: 44-56.
21. Jordan RI, Mulvey MR, Bennett MI. A critical appraisal of gabapentinoids for pain in cancer patients. Curr Opin Support Palliat Care. 2018; 12(2): 108-17.
22. Aoki M, Kurauchi Y, Mori A et al. Comparison of the effects of single doses of elcatonin and pregabalin on oxaliplatin induced cold and mechanical allodynia in rats. Biol Pharm Bull. 2014; 37: 322-6.
23. Peng P, Xi Q, Xia S et al. Pregabalin attenuates docetaxel-induced neuropathy in rats. J Huazhong Univ Sci Technolog Med Sci. 2012; 32: 586-90.
24. Ling B, Coudoré F, Decalonne L et al. Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection. Neuropharmacology. 2008; 55(5): 724-8. http://doi.org/10.1016/j.neuropharm.2008.06.007.
25. Saif MW, Syrigos K, Kaley K et al. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res. 2010; 30(7): 2927-33.
26. Nihei S, Sato J, Kashiwaba M et al. Efficacy and safety of pregabalin for oxaliplatin- and paclitaxel-induced peripheral neuropathy. Gan To Kagaku Ryoho. 2013; 40: 1189-93.
27. Salehifar E, Janbabaei G, Hendouei N et al. Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial. Clin Drug Investig. 2020; 40(3): 249-57. http://doi.org/10.1007/s40261-019-00882-6.
28. Avan R, Janbabaei G, Hendouei N et al. The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane- induced sensory neuropathy: a randomized clinical trial. J Res Med Sci. 2018; 23: 52.
29. Sugimoto M, Takagi T, Suzuki R et al. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer. 2021; 21(1): 1319. http://doi.org/10.1186/s12885-021-09069-9.
30. Hincker A, Frey K, Rao L et al. Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled, crossover study. Pain. 2019; 160(8): 1835-46.
31. Derry S, Bell RF, Straube S et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019; 1: CD007076.
32. Charakterystyka produktu leczniczego: pregabalina.
33. Szczudlik A, Dobrogowski J, Wordliczek J et al. Diagnosis and management of neuropathic pain: Review of literature and recommendations of the Polish Association for the Study of Pain and the Polish Neurological Society – Part one. Neurol Neurochir Pol. 2014; 48: 262-71.
34. Lussier D. Pain Pharmacotherapy in Older Patients. W: Pain 2016: Refresher Courses, 16th World Congress on Pain.
35. Markman JD, Jensen TS, Semel D et al. Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials. Pain Pract. 2017; 17(6): 718-28. http://doi.org/10.1111/papr.12516.
36. Dworkin RH, O`Connor AB, Audette J et al. Recommendations for the pharmacological management of neuropathic pain; an overview and literature update. Mayo Clin Proc. 2010; 85(3 suppl): S3-S14.
37. Johnson P, Becker L, Halpern R et al. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. Clin Drug Investig. 2013; 33(1): 35-44.
38. Holbech JV, Jung A, Jonsson T et al. Combination treatment of neuropathic pain: Danish expert recommendations based on a Delphi process. J Pain Res. 2017; 10: 1467-75.
39. Arnold LM, McCarberg BH, Clair AG et al. Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. Postgrad Med. 2017; 129(8): 921-33. http://doi.org/10.1080/00325481.2017.1384691.
40. Song SY, Ko YB, Kim H et al. Effect of serotonin-norepinephrine reuptake inhibitors for patients with chemotherapy-induced painful peripheral neuropathy: A meta-analysis. Medicine (Baltimore). 2020; 99(1): e18653. http://doi.org/10.1097/MD.0000000000018653.